# A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma 

Source: https://onco.cc/trials/nct06953960/  
OnCo record `nct06953960` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Daratumumab, Dexamethasone, Pomalidomide in multiple myeloma, run by AbbVie, now recruiting.

## Summary

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) is a phase 1/2 interventional study registered as NCT06953960 by AbbVie, with 325 participants planned, started 2025-07-23 and due to reach its primary completion in 2030-12. Interventions recorded: Surzetoclax, Daratumumab, Dexamethasone, Pomalidomide, Etentamig. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06953960
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma
- Sponsor: AbbVie
- Enrolled: 325

## Sources

- ClinicalTrials.gov NCT06953960: https://clinicaltrials.gov/study/NCT06953960

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Daratumumab](https://onco.cc/drugs/daratumumab/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Pomalidomide](https://onco.cc/drugs/pomalidomide/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct06953960.json